Market Access European study shows inequality in access to new medicines PharmaphorumTrade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US's Most-Favoured Nation (MFN) policy.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum Trade organisation EFPIA says disparities in access to new medicines in Europe may be exacerbated by the US’s Most-Favoured Nation (MFN) policy. Read full story Post navigation Previous: Sanofi says drug for rare disease AATD tops standard careNext: UCB reports positive outcomes for bimekizumab in psoriatic arthritis Related Stories Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026 Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026
